These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 8004569)

  • 41. Lymphovascular invasion is independently associated with poor prognosis in patients with localized upper urinary tract urothelial carcinoma treated surgically.
    Saito K; Kawakami S; Fujii Y; Sakura M; Masuda H; Kihara K
    J Urol; 2007 Dec; 178(6):2291-6; discussion 2296. PubMed ID: 17936818
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedules.
    Bajorin DF; McCaffrey JA; Dodd PM; Hilton S; Mazumdar M; Kelly WK; Herr H; Scher HI; Icasiano E; Higgins G
    Cancer; 2000 Apr; 88(7):1671-8. PubMed ID: 10738226
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tissue microarray analysis of the prognostic value of E-cadherin, Ki67, p53, p27, survivin and MSH2 expression in upper urinary tract transitional cell carcinoma.
    Fromont G; Rouprêt M; Amira N; Sibony M; Vallancien G; Validire P; Cussenot O
    Eur Urol; 2005 Nov; 48(5):764-70. PubMed ID: 16126329
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [PPA (cis-platinum), peplomycin and adriamycin) combination chemotherapy in transitional cell carcinoma of the urothelial tract--pilot study].
    Ono Y; Ohshima S; Fujita T; Naide Y; Suzuki K; Asoh Y; Fukushima M; Ohta K
    Nihon Gan Chiryo Gakkai Shi; 1986 Feb; 21(1):28-33. PubMed ID: 2422307
    [No Abstract]   [Full Text] [Related]  

  • 45. Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of survival in patients with metastatic urothelial carcinoma: A multi-institutional study.
    Taguchi S; Nakagawa T; Matsumoto A; Nagase Y; Kawai T; Tanaka Y; Yoshida K; Yamamoto S; Enomoto Y; Nose Y; Sato T; Ishikawa A; Uemura Y; Fujimura T; Fukuhara H; Kume H; Homma Y
    Int J Urol; 2015 Jul; 22(7):638-43. PubMed ID: 25903328
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Predictive Impact of Prognostic Nutritional Index on Pembrolizumab for Metastatic Urothelial Carcinoma Resistant to Platinum-based Chemotherapy.
    Ishiyama Y; Kondo T; Nemoto Y; Kobari Y; Ishihara H; Tachibana H; Yoshida K; Hashimoto Y; Takagi T; Iizuka J; Tanabe K
    Anticancer Res; 2021 Mar; 41(3):1607-1614. PubMed ID: 33788756
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term effects of bacille Calmette-Guérin perfusion therapy for treatment of transitional cell carcinoma in situ of upper urinary tract.
    Hayashida Y; Nomata K; Noguchi M; Eguchi J; Koga S; Yamashita S; Hayashi M; Kanatake H
    Urology; 2004 Jun; 63(6):1084-8. PubMed ID: 15183955
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Survival of patients with transitional cell carcinoma of the ureter and renal pelvis in Balkan endemic nephropathy and non-endemic areas of Serbia.
    Dragicevic D; Djokic M; Pekmezovic T; Micic S; Hadzi-Djokic J; Vuksanovic A; Simic T
    BJU Int; 2007 Jun; 99(6):1357-62. PubMed ID: 17346272
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Combination chemotherapy with M-VAC protocol in metastatic urothelial cancer].
    Sella A; Flex D; Gafni D; Rabinovitz O; Sulkes A; Baniel J
    Harefuah; 1999 Feb; 136(4):268-71, 340, 339. PubMed ID: 10914214
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Clinical Experience from an Expanded Access Study in the United States.
    Pal SK; Hoffman-Censits J; Zheng H; Kaiser C; Tayama D; Bellmunt J
    Eur Urol; 2018 May; 73(5):800-806. PubMed ID: 29478735
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prognostic significance of serum alkaline phosphatase and lactate dehydrogenase levels in patients with unresectable advanced gastric cancer.
    Namikawa T; Ishida N; Tsuda S; Fujisawa K; Munekage E; Iwabu J; Munekage M; Uemura S; Tsujii S; Tamura T; Yatabe T; Maeda H; Kitagawa H; Kobayashi M; Hanazaki K
    Gastric Cancer; 2019 Jul; 22(4):684-691. PubMed ID: 30417313
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: a phase II trial.
    Bajorin DF; McCaffrey JA; Hilton S; Mazumdar M; Kelly WK; Scher HI; Spicer J; Herr H; Higgins G
    J Clin Oncol; 1998 Aug; 16(8):2722-7. PubMed ID: 9704723
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Recurrent and/or metastatic head and neck squamous cell carcinoma: a clinical, univariate and multivariate analysis of response and survival with cisplatin-based chemotherapy.
    Recondo G; Armand JP; Tellez-Bernal E; Domenge C; Belehradek M; De Vathaire F; Wibault P; Richard JM; Cvitkovic E
    Laryngoscope; 1991 May; 101(5):494-501. PubMed ID: 1709437
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prognostic factors influencing survival after nephroureterectomy for transitional cell carcinoma of the upper urinary tract.
    Kobayashi Y; Saika T; Manabe D; Nasu Y; Kumon H
    Acta Med Okayama; 2010 Feb; 64(1):27-31. PubMed ID: 20200581
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Factors affecting the survival of patients treated by standard nephroureterectomy for transitional cell carcinoma of the upper urinary tract.
    Ataus S; Onal B; Tunc B; Erozenci A; Cekmen A; Kural AR; Oner A
    Int Urol Nephrol; 2006; 38(1):9-13. PubMed ID: 16502046
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model.
    Gravis G; Boher JM; Fizazi K; Joly F; Priou F; Marino P; Latorzeff I; Delva R; Krakowski I; Laguerre B; Walz J; Rolland F; Théodore C; Deplanque G; Ferrero JM; Pouessel D; Mourey L; Beuzeboc P; Zanetta S; Habibian M; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Labourey JL; Machiels JP; El Kouri C; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Soulie M; Oudard S
    Eur Urol; 2015 Aug; 68(2):196-204. PubMed ID: 25277272
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Chemotherapy in advanced transitional cell carcinoma of the urinary tract. Phase II trial of a combination of doxorubicin and cisplatin].
    Ribrag V; Ghnassia M; Théodore C; Ghosn M; Piot G; Beurton D; Cukier J; Droz JP
    J Urol (Paris); 1990; 96(7):373-4. PubMed ID: 2290037
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic impact of local radiotherapy on metastatic urothelial carcinoma patients receiving systemic chemotherapy.
    Abe T; Minami K; Harabayashi T; Sazawa A; Chiba H; Kikuchi H; Miyata H; Frumido J; Matsumoto R; Osawa T; Junji I; Tango M; Satoshi C; Tomoshige A; Masashi M; Naoto M; Kunihiko T; Satoru M; Murai S; Shinohara N
    Jpn J Clin Oncol; 2020 Feb; 50(2):206-213. PubMed ID: 31665467
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lymphovascular invasion independently predicts increased disease specific survival in patients with transitional cell carcinoma of the upper urinary tract.
    Kikuchi E; Horiguchi Y; Nakashima J; Hatakeyama N; Matsumoto M; Nishiyama T; Murai M
    J Urol; 2005 Dec; 174(6):2120-3; discussion 2124. PubMed ID: 16280740
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Upper urinary tract transitional cell carcinoma: is there a best?
    Gunay LM; Akdogan B; Koni A; Inci K; Bilen CY; Ozen H
    Clin Genitourin Cancer; 2013 Mar; 11(1):39-44. PubMed ID: 23063580
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.